ELIOS Announces New Research Results Visit our Press Room →

Press Room

June 1, 2018

Elios Therapeutics Announces Interim Phase IIb Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

April 2018

AACR Conference Poster: Initial Analysis of Open-label Administration of Autologous TLPLDC in Melanoma Patients Who Recurred During a Phase IIb Adjuvant Vaccine Trial

April 17, 2018

Elios Therapeutics Presents Initial Phase 2b Results of TLPLDC…at the American Association for Cancer Research (AACR) 2018 Annual Meeting

April 16, 2018

Elios Therapeutics to Present Interim Phase 2b Results of TLPLDC…at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Menu